In a significant legal development that has sent ripples through the genomic diagnostics industry, a US federal court has ordered Guardant Health to pay $245.2 million to TwinStrand Biosciences and the University of Washington (UW). The judgment, handed down by Judge Gregory Williams in the US District Court for the District of Columbia, marks a decisive, though likely temporary, conclusion to a high-stakes intellectual property battle over the foundational technology behind next-generation DNA sequencing.
The ruling upholds and expands upon a November 2023 jury verdict that found Guardant liable for infringing on two core patents held by TwinStrand and the University of Washington. These patents protect the proprietary "Duplex Sequencing" technology, an innovation that has set a new gold standard for accuracy in genomic profiling.
The Core of the Dispute: Duplex Sequencing Technology
At the heart of this litigation is "Duplex Sequencing," a breakthrough technology originally developed at the University of Washington. TwinStrand Biosciences, which spun out from the university in 2015, holds the exclusive rights to this method.
Conventional DNA sequencing methods, while revolutionary, are often plagued by "noise"—errors introduced during the sample preparation and sequencing process. Duplex Sequencing solves this by tagging and tracking both strands of DNA molecules, allowing for error correction that is over 10,000 times more accurate than standard industry techniques. This level of precision is critical in clinical settings, particularly for detecting trace amounts of tumor DNA in cancer patients, where a single false-positive or false-negative can fundamentally alter a treatment path.
The court found that Guardant Health integrated this patented methodology into 11 of its products and services. Among the affected offerings is the Guardant360 CDx, a widely used comprehensive genomic profiling (CGP) assay that provides oncologists with critical data on tumor DNA mutations in patients with advanced solid cancers.
Chronology of the Legal Conflict
The roots of the current tension stretch back several years, culminating in a series of legal milestones:
- August 2021: TwinStrand Biosciences formally files a complaint against Guardant Health, asserting that the latter’s genomic profiling services infringe upon two critical patents protecting their Duplex Sequencing technology.
- November 2023: A jury trial concludes with a verdict against Guardant Health, finding the company liable for patent infringement. The initial jury award was set at $83 million.
- August 2026: Following a period of review and the assessment of accrued damages, Judge Gregory Williams issues the final judgment. The total liability is adjusted to $245.2 million, accounting for the original damages, interest, and substantial royalties accrued between early 2024 and mid-2026.
- Present: Guardant Health publicly announces its intent to appeal the ruling, challenging both the liability finding and the specific financial structure of the ongoing royalty payments.
Breakdown of the $245.2 Million Penalty
The final judgment is a complex calculation that reflects both past infringements and a long-term financial obligation. The $245.2 million figure is not merely a lump-sum punitive measure; it includes:
- Damages and Interest: A portion of the award covers the initial infringement finding established in the 2023 trial.
- Accrued Royalties ($119.4 million): This amount covers the period from February 5, 2024, to May 31, 2026. The court arrived at this figure by applying a 6% royalty levy against a $1.39 billion revenue base generated by the 11 infringing products during that window.
- Ongoing Royalties: Perhaps the most contentious aspect of the ruling is the mandate for future payments. Guardant is now required to pay a 6% royalty on all sales of the covered products and services from June 1, 2026, until the patents expire on March 15, 2033. These payments are to be rendered to TwinStrand and the University of Washington on a quarterly basis.
Perspectives from the Parties
TwinStrand’s Stance: Protecting Innovation
Chad Waite, board chair of TwinStrand, emphasized that the judgment is a victory for inventors and the integrity of academic research. "Duplex Sequencing solved an accuracy problem the sequencing field had worked on for years," Waite stated. "This judgment affirms the jury’s finding that Guardant Health built products on that invention without a license. We remained steadfast in our conviction that the facts would prevail, and they have."
Guardant’s Defense: Disagreement and Appeal
Guardant Health has adopted an aggressive defensive posture, signaling that the legal fight is far from over. John Saia, Guardant’s chief legal officer, stated, "We strongly disagree with this decision and will promptly be appealing for its overturn. We have full faith in the strengths and merits of Guardant’s intellectual property and R&D and are confident we will ultimately prevail on appeal."
Guardant’s legal team further argued that the court’s order is overly broad. They contend that the royalty mandate should be limited to products that existed at the time of the 2023 trial. According to Guardant, many of these products have since been "discontinued or significantly upgraded." Specifically, the company claims that its updated versions of Guardant Reveal and Shield, as well as recent design improvements to the Guardant360 platform, should render them exempt from the 6% royalty requirement.
Financial Implications and Market Reaction
The disclosure of the ruling occurred just before the market opened on August 24. Investors reacted with caution, leading to a 3.6% dip in Guardant’s share price on the Nasdaq, which fell from $170.69 to $164.62. Despite this, the company maintains a robust market capitalization of approximately $21.9 billion, suggesting that while the fine is significant, it is viewed by some market analysts as a manageable setback.
Market analysts at William Blair offered a measured perspective, noting in a research report: "While a negative headline, we don’t think this meaningfully changes the path from here as the increased judgment reflects the passage of time rather than a change in court ruling."
Future Implications for the Genomic Diagnostics Sector
This case serves as a high-profile reminder of the complexities surrounding intellectual property in the rapidly evolving field of precision medicine. As diagnostics companies race to improve the accuracy and speed of their sequencing services, the reliance on foundational patents becomes an increasingly critical factor in corporate strategy.
The Impact of "Design-Around" Efforts
Guardant’s attempt to argue that their current, upgraded technologies fall outside the scope of the original patent infringement highlights a common strategy in the tech and biotech sectors: "designing around" patents. If Guardant succeeds in convincing an appellate court that their newer iterations of these products have effectively moved beyond the scope of TwinStrand’s specific claims, it could create a blueprint for other companies navigating similar patent thickets.
Setting Precedent for Academic-Corporate Relations
The role of the University of Washington as a co-plaintiff underscores the vital relationship between research institutions and the biotech industry. Universities often license their inventions to startups like TwinStrand; when those inventions are potentially misappropriated by larger corporations, the universities have a vested interest in enforcing those rights. This case may embolden academic institutions to take a more active role in litigation to protect the revenue streams derived from their research labs.
Long-Term Market Stability
For the oncology sector, the resolution of this case is closely watched. Any disruption to the availability of Guardant’s testing services would have clinical consequences for patients relying on these assays for cancer management. However, given that the court has ordered a royalty structure rather than an injunction (which would have halted sales), the immediate impact on patient access to these diagnostic tools appears to be minimal.
As the appeal process begins, the industry will be watching to see if the appellate court upholds the royalty structure. If the 6% levy remains in place, it could set a benchmark for future licensing agreements and infringement settlements within the genomic testing space, effectively putting a price tag on the value of "high-accuracy" sequencing technology.
Ultimately, the battle between Guardant Health and TwinStrand is a testament to the high stakes of modern genomic medicine. In a field where accuracy is not just a commercial advantage but a clinical necessity, the boundaries of intellectual property will continue to be tested, litigated, and redefined.
About the Author
